Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”

Detalles Bibliográficos
Autores principales: Munafo, Alain, Krebs-Brown, Axel, Gaikwad, Sumedh, Urgatz, Bogumila, Castello-Bridoux, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584227/
https://www.ncbi.nlm.nih.gov/pubmed/31187469
http://dx.doi.org/10.1007/s40262-019-00785-x
_version_ 1783428487934115840
author Munafo, Alain
Krebs-Brown, Axel
Gaikwad, Sumedh
Urgatz, Bogumila
Castello-Bridoux, Claire
author_facet Munafo, Alain
Krebs-Brown, Axel
Gaikwad, Sumedh
Urgatz, Bogumila
Castello-Bridoux, Claire
author_sort Munafo, Alain
collection PubMed
description
format Online
Article
Text
id pubmed-6584227
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-65842272019-07-05 Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?” Munafo, Alain Krebs-Brown, Axel Gaikwad, Sumedh Urgatz, Bogumila Castello-Bridoux, Claire Clin Pharmacokinet Letter to the Editor Springer International Publishing 2019-06-12 2019 /pmc/articles/PMC6584227/ /pubmed/31187469 http://dx.doi.org/10.1007/s40262-019-00785-x Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Munafo, Alain
Krebs-Brown, Axel
Gaikwad, Sumedh
Urgatz, Bogumila
Castello-Bridoux, Claire
Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_full Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_fullStr Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_full_unstemmed Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_short Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
title_sort comment on “levothyrox(®) new and old formulations: are they switchable for millions of patients?”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584227/
https://www.ncbi.nlm.nih.gov/pubmed/31187469
http://dx.doi.org/10.1007/s40262-019-00785-x
work_keys_str_mv AT munafoalain commentonlevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT krebsbrownaxel commentonlevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT gaikwadsumedh commentonlevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT urgatzbogumila commentonlevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients
AT castellobridouxclaire commentonlevothyroxnewandoldformulationsaretheyswitchableformillionsofpatients

Ejemplares similares